- Published at
- by manilatimes.net
positive
positive
News for Eisai Co., Ltd. (ESALF)
- Published at
- by gurufocus.com
negativenegativeGyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (”Gyre”) ( GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to ad- Published at
- by seekingalpha.com
positivepositiveEisai Stock: Leqembi Approved In EU (OTCMKTS:ESALF)
See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid tariffs and restructuring in pharma.- Published at
- by gurufocus.com
positivepositiveAllarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib's Unique, Dual Therapeutic Mechanism of Action
TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. (”Allarity” or the ”Company”) ( ALLR), a Phase 2 clinical-stage pharmaceutical c- Published at
- by gurufocus.com
positivepositiveAllarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (”Allarity” or the ”Company”) ( ALLR), a Phase 2 clinical-stage pharmaceutic- Published at
- by manilatimes.net
mixedmixed- Published at
- by seekingalpha.com
mixedmixedEisai Co., Ltd. (ESALF) Q4 2025 Earnings Call Transcript
Eisai Co., Ltd. (OTCPK:ESALF) Q4 2025 Earnings Conference Call May 15, 2025 2:30 AM ETCompany ParticipantsHaruo Naito - Representative Corporate Officer...- Published at
- by seekingalpha.com
neutralneutralEisai Co., Ltd. 2024 Q4 - Results - Earnings Call Presentation (OTCMKTS:ESALF)
The following slide deck was published by Eisai Co., Ltd.- Published at
- by gurufocus.com
neutralneutralBeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD”‘1/L1 therapySEE- Published at
- by gurufocus.com
positivepositiveAllarity Therapeutics Announces Participation in Pharma Partnering Summit US
TARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. (”Allarity” or the ”Company”) ( ALLR), a Phase 2 clinical-stage pharmaceutic- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
positivepositiveLeqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia- Published at
- by manilatimes.net
mixedmixed- Published at
- by manilatimes.net
negativenegativePRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets
Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform- Published at
- by manilatimes.net
mixedmixed- Published at
- by gurufocus.com
positivepositiveAllarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
Boston (March 24, 2025)””Allarity Therapeutics, Inc. (”Allarity” or the ”Company”) ( ALLR), a Phase 2 clinical-stage pharmaceutical company de- Published at
- by gurufocus.com
positivepositiveAllarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
The Annual Meeting is the foremost educational and scientific event for gynecologic oncologistsStenoparib has shown clinical benefit in heavily pre-treate- Published at
- by gurufocus.com
positivepositiveAllarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
Boston (March 13, 2025)””Allarity Therapeutics, Inc. (”Allarity” or the ”Company”) ( ALLR), a Phase 2 clinical-stage pharmaceutical company dedicate- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
mixedmixed